Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors

PLoS ONE(2021)10.1371/journal.pone.0256937Source: DataRank Database

Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors is a research paper published in PLoS ONE (2021). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)OA: goldTopics (49)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Logan George,Ssu-Hsueh Tseng,Brandon Lam ORCID,Srinidhi Polkampally ORCID,Anjali D. Amiano

Live enrichment

PubMed:34506530 PMC:PMC8432795

National Cancer Institute

Grant: P50CA098252

National Cancer Institute

Grant: P50CA228991

National Cancer Institute

Grant: P30CA06973

Ovarian Cancer Research Fund Alliance

Grant: 458972

NIGMS NIH HHS

Grant: R25 GM109441

NCI NIH HHS

Grant: P30 CA006973

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

National Institutes of Health

Grant: 5P50CA228991-02

SPORE in Ovarian Cancer

National Institutes of Health

Grant: 5P50CA098252-17

SPORE in Cervical Cancer

Allegheny Health Network

goldLicense: cc-by

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0256937&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0256937

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8432795

repositoryhttps://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d

Europe_PMChttps://europepmc.org/articles/PMC8432795

Fields of Study

0301 basic medicine03 medical and health sciencesAnimalsAntineoplastic AgentsApoptosisBenzylidene CompoundsCell Line, TumorCell ProliferationFemaleHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred C57BLMice, NudeOvarian NeoplasmsUbiquitination

MeSH Terms

Cell Line, TumorAnimalsMice, Inbred C57BLHumansMiceMice, NudeOvarian NeoplasmsBenzylidene CompoundsIntracellular Signaling Peptides and ProteinsAntineoplastic AgentsApoptosisCell ProliferationFemaleUbiquitination

Keywords

Ovarian NeoplasmsScienceQRIntracellular Signaling Peptides and ProteinsUbiquitinationMice, NudeAntineoplastic AgentsApoptosisBenzylidene CompoundsMice, Inbred C57BLMiceCell Line, TumorMedicineAnimalsHumansFemaleResearch ArticleCell Proliferation

Sustainable Development Goals

SDG 3: 3. Good health

Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors

FAIR Checklist

Authors (16)

Funding (10 grants)

Open Access

Topics

Annotations (Europe PMC)